Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Clin Cancer Res. 2011 Nov 16;18(1):290–300. doi: 10.1158/1078-0432.CCR-11-2260

Figure 1. Locoregional Recurrence (LRR) occurs more frequently in patients with tumors expressing TP53 disruptive mutations.

Figure 1

(A) LRR in the study population in patients with either wild type TP53 or any TP53 mutation (p=0.9). (B) LRR in the same group of patients with the indicated TP53 status.